Presidio Medical

High-Level Overview

Presidio Medical is a clinical-stage medical device company developing the Ultra Low Frequency (ULF™) Neuromodulation System, a spinal cord stimulation (SCS) therapy targeting chronic nociceptive pain, particularly low back pain, where conventional treatments have failed.[1][3][4] The platform serves patients with limited therapeutic options by delivering ultra-low frequency signals via implanted epidural leads to suppress neuronal responses, reducing pain signals and providing long-lasting relief in a minimally invasive manner.[1][3][5] It addresses a $20B market opportunity in nociceptive back pain, with no approved SCS options currently available, and recent FDA Investigational Device Exemption (IDE) approval enables a pivotal randomized controlled trial (FULFILL Study) in the US and Australia.[3]

Growth momentum includes a $72M Series C funding round in 2023 led by Deerfield Management, first-in-human trial results presented in 2025, peer-reviewed publication in *Science Translational Medicine* validating its mechanism, and key hires like CFO Dimas Jiménez.[3][4][5]

Origin Story

Presidio Medical was founded in 2017 in South San Francisco (initially noted as San Francisco-based) as a private company focused on neuromodulation devices using ultra-low frequency (ULF) biphasic currents to block nerve action potentials without tissue damage, mimicking DC effects safely.[4][5] The idea emerged from innovative science blending circuit design, computational modeling, material science, neuroscience, and electrochemistry, aiming to transform pain treatment beyond traditional SCS.[1][5]

Early traction came from preclinical animal models, computational studies, and a first-in-human clinical trial in Australia, with results presented by Dr. Marc Russo at NANS in 2025 showing encouraging safety and efficacy; a 2021 *Science Translational Medicine* paper further validated its unique pain-blocking mechanism across global collaborators.[3][5] CEO Michael Onuscheck has led pivotal milestones like FDA IDE approval.[3]

Core Differentiators

• Unique ULF Mechanism: Delivers ultra-low frequency waveforms to deeply suppress neuronal responses and inhibit axonal conduction, targeting nociceptive pain (e.g., low back) where standard SCS fails; preclinical and clinical data show reversible blocking of pain signals to the thalamus.[1][3][5]
• Broad Applicability: Designed for chronic pain across types with unmet needs, with potential expansion to other indications involving undesired nerve activity; no approved SCS for nociceptive pain creates first-mover advantage.[1][3][5]
• Clinical Validation: Backed by peer-reviewed research in *Science Translational Medicine*, first-in-human trial success, and FDA IDE for pivotal FULFILL Study; differentiates from conventional high-frequency SCS via superior efficacy in models.[3][4][5]
• Patient-Centric Design: Minimally invasive epidural delivery for durable relief, focusing on underserved patients; recent funding scales manufacturing and trials.[3][4]

Role in the Broader Tech Landscape

Presidio Medical rides the neuromodulation wave in medtech, addressing chronic pain amid rising demand for non-opioid, targeted therapies amid the opioid crisis and SCS market growth.[1][3][5] Timing aligns with FDA IDE approval in 2025, enabling US pivotal trials post-positive Australia data, capitalizing on a $20B nociceptive pain gap.[3]

Market forces favor it: aging populations drive chronic pain prevalence, while neuromodulation advances (e.g., waveform innovations) outpace pharmacology; Presidio influences the ecosystem by pioneering ULF tech, potentially expanding SCS to nociceptive pain and new indications, fostering research collaborations (e.g., King's College, University of Michigan).[4][5] Its $72M funding supports scaling amid investor interest in durable, mechanism-proven devices.[4]

Quick Take & Future Outlook

Presidio Medical is poised for commercialization post-FULFILL Study results, with FDA IDE unlocking pivotal data to support approval for chronic low back pain and platform expansion.[3] Trends like AI-enhanced neuromodulation, non-opioid mandates, and personalized nerve therapies will shape its path, potentially capturing significant share in a burgeoning SCS market.

Influence may evolve from clinical innovator to ecosystem leader, licensing ULF tech or entering adjacent fields, building on its differentiated mechanism to reduce global pain suffering—transforming neuromodulation as promised from day one.[1][5]